Genomic Bioinformatics Laboratory, Department of Molecular Biology, Ariel University, Ariel, 40700, Israel.
The Krieger Eye Research Laboratory, Felsenstein Medical Research Center, Beilinson Hospital, Petach Tikva 4941492, affiliated to Tel Aviv University, Tel Aviv, 6997801, Israel.
Sci Rep. 2017 Jun 16;7(1):3648. doi: 10.1038/s41598-017-03892-6.
In pediatric brain tumours, dissemination of malignant cells within the central nervous system confers poor prognosis and determines treatment intensity, but is often undetectable by imaging or cytology. This study describes the use of fluorescence lifetime (FLT) imaging microscopy (FLIM), a novel diagnostic tool, for detection of metastatic spread. The study group included 15 children with medulloblastoma and 2 with atypical teratoid/rhabdoid tumour. Cells extracted from the tumour and the cerebrospinal fluid (CSF) 2 weeks postoperatively and repeatedly during chemo/radiotherapy were subjected to nuclear staining followed by FLT measurement and cytological study. Control CSF samples were collected from patients with infectious/inflammatory disease attending the same hospital. Median FLT was prolonged in tumour cells (4.27 ± 0.28 ns; P < 2.210) and CSF metastatic cells obtained before chemo/radiotherapy (6.28 ± 0.22 ns; P < 2.210); normal in inflammatory control cells (2.6 ± 0.04 ns) and cells from children without metastasis before chemo/radiotherapy (2.62 ± 0.23 ns; P = 0.858) and following treatment (2.62 ± 0.21 ns; P = 0.053); and short in CSF metastatic cells obtained after chemo/radiotherapy (2.40 ± 0.2 ns; P < 2.2*10). FLIM is a simple test that can potentially identify CSF spread of brain tumours. FLT changes in accordance with treatment, with significant prolonged median values in tumours and metastases. More accurate detection of metastatic cells may guide personalised treatment and improve the therapeutic outcome.
在儿科脑肿瘤中,恶性细胞在中枢神经系统内的扩散会导致预后不良,并决定治疗强度,但通常无法通过影像学或细胞学检测到。本研究描述了使用荧光寿命(FLT)成像显微镜(FLIM)这一新型诊断工具来检测转移性扩散。研究组包括 15 名患有髓母细胞瘤和 2 名患有非典型畸胎瘤/横纹肌样瘤的儿童。术后 2 周和化疗/放疗过程中反复从肿瘤和脑脊液(CSF)中提取细胞,进行核染色,然后进行 FLT 测量和细胞学研究。对照 CSF 样本取自在同一医院就诊的感染/炎症性疾病患者。肿瘤细胞和化疗/放疗前获得的 CSF 转移性细胞的中位 FLT 延长(肿瘤细胞为 4.27±0.28 ns;P<2.210;CSF 转移性细胞为 6.28±0.22 ns;P<2.210);化疗/放疗前无转移的儿童的炎性对照细胞(2.6±0.04 ns)和细胞以及治疗后的细胞(2.62±0.23 ns;P=0.858)和治疗后的细胞(2.62±0.21 ns;P=0.053)正常;化疗/放疗后获得的 CSF 转移性细胞的 FLT 较短(2.40±0.2 ns;P<2.2*10)。FLIM 是一种简单的测试方法,有可能识别 CSF 中脑肿瘤的扩散。FLT 随治疗而变化,肿瘤和转移灶的中位值显著延长。更准确地检测转移性细胞可能有助于指导个体化治疗并改善治疗效果。